| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/31/2008 | CA2675142A1 Fused aromatic difluoromethanephosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 07/31/2008 | CA2674908A1 Tri-demethylation-capable protein complex, method of its preparation and its use |
| 07/31/2008 | CA2674897A1 Cancerous disease modifying antibodies |
| 07/30/2008 | EP1950301A2 Antibody for use in Therapy |
| 07/30/2008 | EP1950300A2 Antibody variants with higher binding affinity compared to parent antibodies |
| 07/30/2008 | EP1950299A1 Mammalian receptor proteins; related reagents and methods |
| 07/30/2008 | EP1950297A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 07/30/2008 | EP1950293A1 Method for prediction of effectiveness of rar- agonist |
| 07/30/2008 | EP1950286A1 Tri-demethylation-capable protein complex, method of its preparation and its use |
| 07/30/2008 | EP1950224A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950223A2 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 07/30/2008 | EP1950217A1 Organometallic compounds for the treatment of cancer |
| 07/30/2008 | EP1950201A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| 07/30/2008 | EP1950199A1 Proline derivatives and use thereof as drugs |
| 07/30/2008 | EP1949936A2 Controlled release composition and method of producing the same |
| 07/30/2008 | EP1949915A2 Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients |
| 07/30/2008 | EP1949912A2 Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody |
| 07/30/2008 | EP1949911A2 Treatment of chronique lymphocytic leukemia using chimeric anti-CD20 antibody. |
| 07/30/2008 | EP1949910A1 Treatment of chronic lymphocytic leukemia (CLL) using chimeric anti-CD20 antibody. |
| 07/30/2008 | EP1949905A1 Reovirus for the treatment of cellular proliferative disorders |
| 07/30/2008 | EP1949899A1 Metal salophen complexes use in prevention and treatment of cancer |
| 07/30/2008 | EP1949898A1 Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| 07/30/2008 | EP1949107A1 Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells |
| 07/30/2008 | EP1948818A2 Use of b cell expansion agents in generating antibodies |
| 07/30/2008 | EP1948798A1 Anti-alpha2 integrin antibodies and their uses |
| 07/30/2008 | EP1948788A1 Method of expanding double negative t cells |
| 07/30/2008 | EP1948693A1 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 07/30/2008 | EP1948664A2 Pyrrolotriazine kinase inhibitors |
| 07/30/2008 | EP1948663A2 Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
| 07/30/2008 | EP1948657A1 Azaindazoles useful as inhibitors of kinases |
| 07/30/2008 | EP1948651A1 Thiazole analogues and uses thereof |
| 07/30/2008 | EP1948647A1 Pyrimidinyl-thiophene kinase modulators |
| 07/30/2008 | EP1948623A2 Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 07/30/2008 | EP1948617A2 Pyrimidinones as casein kinase ii (ck2) modulators |
| 07/30/2008 | EP1948242A2 Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| 07/30/2008 | EP1948240A2 Ligand conjugates of vinca alkaloids, analogs and derivatives |
| 07/30/2008 | EP1948225A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
| 07/30/2008 | EP1948215A1 Inhibitors of parp activity and uses thereof |
| 07/30/2008 | EP1948213A2 Methods to predict and prevent resistance to taxoid compounds |
| 07/30/2008 | EP1948196A2 Use of tetraorganosilicon compounds |
| 07/30/2008 | EP1948195A2 Improved methods of using phosphoantigen for the treatment of cancer |
| 07/30/2008 | EP1948185A2 Inhibitors of akt activity |
| 07/30/2008 | EP1948180A1 Combination treatment of cancer comprising egfr/her2 inhibitors |
| 07/30/2008 | EP1948179A1 Quinazoline derivatives for the treatment of cancer diseases |
| 07/30/2008 | EP1948171A1 New method for treating cancer based on the modulation of calcineurin |
| 07/30/2008 | EP1948128A2 Substance for restoring normal co-expression and interaction between lox and nrage proteins |
| 07/30/2008 | EP1742952B1 (poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents |
| 07/30/2008 | EP1737462B1 Pyrimidines with tie2 (tek) activity |
| 07/30/2008 | EP1654210B1 Stilbene derivatives and their use in medicaments |
| 07/30/2008 | EP1653943B3 Catechol derivatives for the treatment of cancer |
| 07/30/2008 | EP1565547B1 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 07/30/2008 | EP1531817B1 Glycinamide derivatives as raf-kinase inhibitors |
| 07/30/2008 | EP1503803B1 Injectable pharmaceutical composition comprising ethanol for treating herniated invertebral discs |
| 07/30/2008 | EP1494752B1 Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 07/30/2008 | EP1480993B1 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 07/30/2008 | EP1478394B1 Stabilized TNFR-Fc composition comprising arginine |
| 07/30/2008 | EP1465995B1 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/30/2008 | EP1423525B1 Recombinant mva capable of expressing structural hcv antigens |
| 07/30/2008 | EP1254124B1 Dipeptide nitrile cathepsin k inhibitors |
| 07/30/2008 | EP1226170B1 Human chordin and polynucleotides encoding the same |
| 07/30/2008 | EP1041977B1 Use of ppar-gamma activators for treating dermatological disorders |
| 07/30/2008 | EP1025124B1 Low-toxicity human interferon-alpha analogues |
| 07/30/2008 | EP0912738B1 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 07/30/2008 | CN101233156A CD19 antibodies and their uses |
| 07/30/2008 | CN101233155A 人抗表皮生长因子受体抗体 Human anti-epidermal growth factor receptor antibody |
| 07/30/2008 | CN101233136A Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| 07/30/2008 | CN101233125A Antitumoral compounds |
| 07/30/2008 | CN101233117A Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy |
| 07/30/2008 | CN101233111A Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same |
| 07/30/2008 | CN101233100A An impurity of anastrozole intermediate, and uses thereof |
| 07/30/2008 | CN101232901A Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 07/30/2008 | CN101232894A Anticancer agent to be combined with telomelysin |
| 07/30/2008 | CN101232892A Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| 07/30/2008 | CN101232880A Use of HDAC inhibitors for the treatment of myeloma |
| 07/30/2008 | CN101232879A Compounds having anti-cancer properties |
| 07/30/2008 | CN101231233A Method for controlling release velocity of fluorescent probe molecule in emulsions |
| 07/30/2008 | CN101230339A Bombina maxima non-crystalline beta gamma-crystallin and trefoil factor protein compound and gene as well as preparation and use thereof |
| 07/30/2008 | CN101230100A Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/30/2008 | CN101230083A Novel glycyrrhetinic acid derivatives and preparation method thereof |
| 07/30/2008 | CN101230082A 23-hydroxy betulinic acid derivative, preparation method, preparation and use thereof |
| 07/30/2008 | CN101230081A Extraction method for separating antineoplastic tri-terpenoid from capsule of weeping forsythia and use thereof |
| 07/30/2008 | CN101230079A 1,2-glycoside transderivative of oxazole compounds and preparation method thereof |
| 07/30/2008 | CN101230074A Phosphate derivative of oxazole compounds and preparation method thereof |
| 07/30/2008 | CN101230068A Polyether triterpene compound as well as preparation method and application thereof |
| 07/30/2008 | CN101230064A 9 methylene aryl substituted purine derivative |
| 07/30/2008 | CN101230049A Hydroxamic acid histone deacetylase inhibitor as well as preparation method and use thereof |
| 07/30/2008 | CN101230045A Aromatic triazin derivatives and uses thereof |
| 07/30/2008 | CN101230043A 3-oxide-2-methylamide derivatives as well as preparation method and use thereof |
| 07/30/2008 | CN101230040A Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins |
| 07/30/2008 | CN101230037A Anti-cancer drug compounds and method for synthesizing same |
| 07/30/2008 | CN101230015A Substituted cinnamic acid derivatives containing amine substituent group and expression purification cytotoxicity thereof |
| 07/30/2008 | CN101229997A 2-methylene-5-substituted methylene cyclopentanone derivatives and uses thereof |
| 07/30/2008 | CN101229381A Acute promyelocytic leukemia DNA vaccine, preparing method thereof and applications |
| 07/30/2008 | CN101229371A Use of anti-TNFalpha antibodies and another drug |
| 07/30/2008 | CN101229362A Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine |
| 07/30/2008 | CN101229348A Chinese traditional medicine compounds for treating tumour and preparing method thereof |
| 07/30/2008 | CN101229340A Applications of Baofukang suppository on preparing medicine for treating cervical carcinoma |
| 07/30/2008 | CN101229335A Method of enzyme method preparing smilax scobinicaulis total saponin extract |
| 07/30/2008 | CN101229286A Compounds of vitamin and plant extract |
| 07/30/2008 | CN101229278A Medicine compounds for treating rectum cancer and gastric cancer |